Surabhi Dangi-Garimella

A retrospective analysis conducted by researchers at Kaiser Permanente and UCLA has concluded that patients with breast cancer treated with aromatase inhibitors (AIs) as adjuvant endocrine therapy were at equal risk of serious cardiovascular disease (CVD) events as those treated with tamoxifen.

The results of this study underscore the importance of advance care planning in improving the quality of care that patients receive at end-of-life.